Tagged with UK

Canada Having managed the Canadian affiliate of Otsuka from its infancy steps, Allison Rosenthal, general manager, highlights the affiliate’s feat to exceed expectations for the performance of each of its launches while maintaining extremely high employee engagement. Otsuka’s specialization in mental health also leads Rosenthal to call for better support from…

UK Aisling Burnand, CEO of the Association of Medical Research Charities (AMRC), shares the organization’s vision and the significant contributions of its member charities to the life sciences R&D ecosystem in the UK. She also outlines some of the main trends within the sector including digitalization and new models of fundraising,…

UK Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and policy changes in the future.   Although the MS community is fairly small, the science is telling us that with…

UK Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia research, the strengths and weaknesses of the UK’s medical research environment, and the potential effects of Brexit.   In all…

UK Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners with the NHS. In addition to your role at Sandoz, you are also one of the founding members of the…

UK Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as a model for the UK post-Brexit. Can you start by introducing the British Swiss Chamber of Commerce so we can…

UK John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the overall UK economy, and why self-care remains a priority. A year after becoming chief executive of the PAGB, the UK…

UK Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why was there a need to create yet another life sciences cluster four years ago? Aren’t there already enough in this…

UK In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his thoughts on the establishment of NICE in 1999, transparency and the evaluation of cost-effectiveness as the organization’s hallmarks, the dialogue…

UK Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may present some solution to the problems the NHS is currently facing. In a career spanning over 30 years of service…

UK British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of facilitating accelerated access to medicines, and the potential fallout from Brexit to the UK’s life sciences ecosystem.   On the…

UK Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits of inter-stakeholder collaboration. Entering 2018, three key themes affecting the British generics industry are Brexit, a new life science industry…